208TiP SOLTI-1303 PATRICIA: Cohort C. Combination of palbociclib with trastuzumab and endocrine therapy (ET) versus treatment of physician’s choice (TPC) in pretreated HER2-positive and hormone receptor-positive (HER2+/HR+) / PAM50 luminal metastatic breast cancer (BC): A randomized phase II trial

E.M. Ciruelos,J. Ponce,S. Pernas Simon,J. Cortés,B. Cantos,E. Garate,E. Vega Alonso,M. Mele Olive,E. Martinez De Dueñas, A. Montaño Perianez,N. Martinez,A. Perello Martorell,B. Bermejo De Las Heras, C. Arqueros Nunez, I. Fernández,J. De la Haba Rodriguez,M. Oliveira,X. González,P. Villagrasa Gonzalez,A. Prat

Annals of Oncology（2022）

引用 1|浏览5

暂无评分

摘要

Efficacy and safety analysis from PATRICIA’s cohorts A & B showed that palbociclib plus trastuzumab is safe, exhibiting promising survival outcomes in trastuzumab pretreated HER2+/HR+ PAM50 Luminal A/B advanced BC (Ciruelos E. et al, CCR 2020), that were maintained after a median of >3 years of follow-up. Based on these encouraging results, PATRICIA trial is currently randomizing patients with HER2+/HR+, PAM50 Luminal tumors to palbociclib, trastuzumab and ET or TPC.

查看译文

关键词

luminal metastatic breast cancer,breast cancer,endocrine therapy,trastuzumab,receptor-positive

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要